Amgen Inc. (AMGN) is a publicly traded company in the Healthcare sector, operating within the Drug Manufacturers - General industry. The company is headquartered in Thousand Oaks, CA, United States. The current CEO is Robert A. Bradway.
AMGN has IPO date of 1983-06-17, 28,000 full-time employees, listed on the NASDAQ Global Select, a market capitalization of $189.19B.
Amgen Inc. is a global biopharmaceutical company that discovers, develops, manufactures, and delivers human therapeutics across key therapeutic areas including inflammation, oncology, bone health, cardiovascular disease, nephrology, and neuroscience. The company's extensive portfolio includes major brands such as Enbrel for rheumatoid arthritis and psoriasis, Neulasta for chemotherapy side effects, Prolia for osteoporosis, Repatha for cardiovascular risk reduction, and KYPROLIS for multiple myeloma, among many others. Amgen distributes its products through pharmaceutical wholesalers and direct-to-consumer channels to healthcare providers including physicians, hospitals, dialysis centers, and pharmacies worldwide. The company actively pursues strategic collaborations with leading pharmaceutical and biotechnology partners to advance its pipeline and expand treatment options across multiple disease areas. Founded in 1980 and headquartered in Thousand Oaks, California, Amgen has established itself as a leader in the global biopharmaceutical industry.
